<?xml version="1.0" encoding="UTF-8"?>
<ref id="pntd.0008336.ref059">
 <label>59</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Arastu-Kapur</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Anderl</surname>
   <given-names>JL</given-names>
  </name>, 
  <name>
   <surname>Kraus</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Parlati</surname>
   <given-names>F</given-names>
  </name>, 
  <name>
   <surname>Shenk</surname>
   <given-names>KD</given-names>
  </name>, 
  <name>
   <surname>Lee</surname>
   <given-names>SJ</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events</article-title>. 
  <source>Clin Cancer Res</source>. 
  <year>2011</year>;
  <volume>17</volume>(
  <issue>9</issue>):
  <fpage>2734</fpage>â€“
  <lpage>43</lpage>. 
  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1950</pub-id>
  <?supplied-pmid 21364033?>
  <pub-id pub-id-type="pmid">21364033</pub-id>
 </mixed-citation>
</ref>
